Cargando…

Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus

Hypoglycaemia is a common side‐effect of diabetes therapies, particularly insulin, and imposes a substantial burden on individuals and healthcare systems. Consequently, regulatory approval of newer basal insulin (BI) therapies has relied on demonstration of a balance between achievement of good glyc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frier, Brian M., Ratzki‐Leewing, Alexandria, Harris, Stewart B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2019
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767397/ https://www.ncbi.nlm.nih.gov/pubmed/30924567 http://dx.doi.org/10.1111/dom.13732

Ejemplares similares

Real-World Effects of Second-Generation Versus Earlier Intermediate/Basal Insulin Analogues on Rates of Hypoglycemia in Adults with Type 1 and 2 Diabetes (iNPHORM, US)
por: Black, Jason E., et al.
Publicado: (2023)

Family Members: The Forgotten Players in the Diabetes Care Team (The TALK-HYPO Study)
por: Ratzki-Leewing, Alexandria, et al.
Publicado: (2019)

Real‐world risk factors of confirmed or probable COVID‐19 in Americans with diabetes: A prospective, community‐based study (iNPHORM)
por: Ratzki‐Leewing, Alexandria, et al.
Publicado: (2022)

Moving Beyond the Stigma: Systematic Review of Video Games and Their Potential to Combat Obesity
por: Guy, Stacey, et al.
Publicado: (2011)

COVID-19 Impact on Diabetes Management (iNPHORM, USA)
por: Ratzki-Leewing, Alexandria, et al.
Publicado: (2021)

Hypoglycaemia in adults with insulin‐treated diabetes in the UK: self‐reported frequency and effects
por: Frier, B. M., et al.
Publicado: (2015)

COVID-19 hinterland: surveilling the self-reported impacts of the pandemic on diabetes management in the USA (cross-sectional results of the iNPHORM study)
por: Ratzki-Leewing, Alexandria A, et al.
Publicado: (2021)

Real-world crude incidence of hypoglycemia in adults with diabetes: Results of the InHypo-DM Study, Canada
por: Ratzki-Leewing, Alexandria, et al.
Publicado: (2018)

Severe hypoglycaemia in adults with insulin‐treated diabetes: impact on healthcare resources
por: Heller, S. R., et al.
Publicado: (2015)

Predicting Real-world Hypoglycemia Risk in American Adults With Type 1 or 2 Diabetes Mellitus Prescribed Insulin and/or Secretagogues: Protocol for a Prospective, 12-Wave Internet-Based Panel Survey With Email Support (the iNPHORM [Investigating Novel Predictions of Hypoglycemia Occurrence Using Real-world Models] Study)
por: Ratzki-Leewing, Alexandria, et al.
Publicado: (2022)

Health Care Providers’ Emotional Responses to Their Patients’ Hypoglycemic Events: Qualitative Findings From the InHypo-DM Study, Canada
por: Brown, Judith Belle, et al.
Publicado: (2021)

Insulin Hypoglycæmia
Publicado: (1948)

Treatment and prevention of severe hypoglycaemia in people with diabetes: Current and new formulations of glucagon
por: Thieu, Vivian T., et al.
Publicado: (2020)

Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials
por: Rosenstock, Julio, et al.
Publicado: (2016)

Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs
por: Signorovitch, J E, et al.
Publicado: (2013)

Association of hypoglycaemia severity with clinical, patient‐reported and economic outcomes in US patients with type 2 diabetes using basal insulin
por: Meneghini, Luigi F., et al.
Publicado: (2018)

Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2
por: Heller, Simon R., et al.
Publicado: (2019)

Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA
por: Mauricio, Dídac, et al.
Publicado: (2017)

Successful Treatment with Bedtime Basal Insulin Added to Metformin without Weight Gain or Hypoglycaemia over Three Years
por: Mertes, Bernardo, et al.
Publicado: (2020)

Short Report: Treatment Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal–Bolus Type 1): 2-year results of a randomized clinical trial
por: Bode, B W, et al.
Publicado: (2013)

Approach to assessing the economic impact of insulin‐related hypoglycaemia using the novel Local Impact of Hypoglycaemia Tool
por: Parekh, W. A., et al.
Publicado: (2015)

The importance of the initial period of basal insulin titration in people with diabetes
por: Khunti, Kamlesh, et al.
Publicado: (2020)

Cognitive deficits associated with impaired awareness of hypoglycaemia in type 1 diabetes
por: Hansen, Tor I., et al.
Publicado: (2017)

Glucagon Administration by Nasal and Intramuscular Routes in Adults With Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover Study
por: Suico, Jeffrey G., et al.
Publicado: (2020)

A meta‐analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia
por: Heller, S., et al.
Publicado: (2015)

The consequences of hypoglycaemia
por: Amiel, Stephanie A.
Publicado: (2021)

Glucose/insulin-glargine/insulin-lispro: Hepatic glycogenosis, hypoglycaemia and acute hepatitis: case report
Publicado: (2021)

Clinical approaches to treat impaired awareness of hypoglycaemia
por: Farrell, Catriona M., et al.
Publicado: (2021)

Previously unrecognized risk factors for severe hypoglycaemia requiring emergency medical care in insulin‐treated type 2 diabetes: Results from a real‐world nested case‐control study
por: Settles, Julie, et al.
Publicado: (2022)

Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used
por: Norwood, Paul, et al.
Publicado: (2017)

Basal Insulin Reduces Glucose Variability and Hypoglycaemia Compared to Premixed Insulin in Type 2 Diabetes Patients: A Study Based on Continuous Glucose Monitoring Systems
por: Wang, Huiying, et al.
Publicado: (2022)

Risk of clinically relevant hypoglycaemia in patients with type 2 diabetes self‐titrating insulin glargine U‐100
por: Hollander, Priscilla A., et al.
Publicado: (2019)

Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment
por: Tien, Kai‐Jen, et al.
Publicado: (2019)

Challenges and unmet needs in basal insulin therapy: lessons from the Asian experience
por: Chan, Wing Bun, et al.
Publicado: (2017)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
por: Nasrallah, Sami N., et al.
Publicado: (2012)

Cost of severe hypoglycaemia in patients with type 1 diabetes in Spain and the cost-effectiveness of insulin lispro compared with regular human insulin in preventing severe hypoglycaemia
por: Reviriego, J, et al.
Publicado: (2008)

Hypoglycæmia
Publicado: (1934)

Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes
por: Rodbard, H W, et al.
Publicado: (2014)

Concentrated insulins: the new basal insulins
por: Lamos, Elizabeth M, et al.
Publicado: (2016)

Tacrolimus: Hypoglycaemia: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fs9bpdd3kofefmg9igq7knotds